Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous bone marrow mononuclear cell therapy with or without repeat angioplasty versus repeat angioplasty in diabetic foot peripheral arterial disease
2016-001398-34Phase 2Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Apr 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous bone marrow-derived mononuclear cell in arteriosclerosis obliterans and diabetic foot syndrome (3 arms), sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Comparison of both methods in several parameters. Started Apr 2016; status: completed.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
arteriosclerosis obliteransdiabetic foot syndrome
Beyond the preview
Go deeper on 2016-001398-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001398-34.